8,082 trials (keyword fallback)
Chagas Disease
Primary: Part 1 - Percentage of Sero-reduction or Sero-conversion (Cured Subjects) — 32.9; 18.9 Percentage of subjects
Healthy
Primary: PRISM Chagas Specificity — 23; 16223; 3 participants
Chagas Disease
Primary: ESA Chagas Testing of US Blood Donor Specimens Repeatedly Reactive by ABBOTT PRISM Chagas — 92.06 percent agreement to RIPA
Chagas Disease
Primary: Percentage of Participants With a Successful Response as Measured by Qualitative Polymerase Chain Reaction — 15.6; 10.0; 82.1; 86.7 Percentage of participants
Chagas Disease
Primary: Correlation Between Longitudinal Global Strain and the Percentage of Myocardial Fibrosis on Magnetic Resonance — 16.8 percentage of fibrosis
Dilated Cardiomyopathy
Primary: Heart Failure Mortality — 8; 19 participants — p=0.01
Chagas Disease · Heart Failure
Primary: Hierarchical Composite Endpoint Composed of Time to Cardiovascular (CV) Death, Time to First Heart Failure (HF) Hospitalization, and Relative Change in NT-proBNP From…
Chronic Kidney Disease
Primary: Whole Blood Platelet Aggregation to 0.5 Millimoles Arachidonic Acid — 21.0; 18.0; 0; 0 ohms
Scleroderma
Primary: Improvement in the Modified Rodnan Skin Score. — 46.75 percent improvement from baseline
Rheumatoid Arthritis
Primary: Mean 48-week Change in DAS28 — -2.12; -2.29 units on a scale
Gaucher Disease
Primary: Number of Severe Adverse Events (SAE) — 1 events
Dupuytren's Disease
Primary: Early Disease: Nodule Hardness at 12 Months — 58.1; 61.2 Durometer Arbitrary Units (AU)
Kidney Cancer
Primary: Percentage of Participants With Response — 0; 15; 65; 10 percentage of participants
Alopecia Areata
Primary: Change in SALT Score — 65.8; 24.8; 7.3 score on a scale
Multiple Sclerosis
Primary: Number of Patients With a Return of Disease Activity After the Third Month Post-first-infusion — 3; 6 Participants